Pune scientists develop tech to detect early spread of cancer

Image
Press Trust of India Mumbai
Last Updated : Aug 19 2019 | 4:35 PM IST

A group of Pune-based scientists have developed a 'liquid biopsy' technology to detect early spread of cancer and claim it is the fastest in the world.

The 'OncoDiscover' technology has been approved by the Central Drugs Standard Control Organisation, the national regulatory body for pharmaceuticals and medical devices, they said.

"This technology is expected to revolutionise the early diagnosis and management of cancer patients in India," said Dr Jayant Khandare, Chief Scientific Officer of Actorius Innovations and Research, a Pune-based start-up.

"OncoDiscover is the first-of-its-kind to be licensed to manufacture for sale under the new Medical Device Guidelines, 2017, for early detection of metastasis in epithelial origin cancers," he said.

Actorius has indigenously developed the more specific, highly rapid and efficient cancer diagnostic technology in detecting the early spread of cancers, Khandare told PTI.

The start-up has been funded for high-risk innovations by the Biotechnology Industry Research Assistance Council, an industry support wing of the Department of Biotechnology, he said.

A team of scientists led by Khandare and Aravindan Vasudevan worked to crack the technological challenges in detecting circulating tumor cells (CTCs) from lung, breast, colorectal, head and neck cancers.

"CTCs are extremely low in numbers, as low as one CTC is accounted for in millions of other blood cells. Their isolation and enumeration in a patient's blood is like finding a needle in a haystack," Khandare said.

The new technology has been patented internationally and "clinically validated" via multiple clinical trials, he said. One such was undertaken by Dr Pankaj Chaturvedi, noted oncologist and deputy director at the Tata Memorial Hospital in Mumbai.

While a similar CTC detection test approved by the US FDA costs USD 1,000 and is unaffordable for most Indians, OncoDiscover comes at a fraction of that cost, he said.

The test is now available in Pune at the OncoDiscover Liquid Biopsy Technology lab for cancer patients in India, he added.

Khandare was in 2011 awarded the Alexander von Humboldt Experienced Researcher Fellowship for his research in macromolecular chemistry, involving work on targeting cancer cells and in inflammation using ligands and hyper-branched polymers.

The Germany-based Humboldt Foundation gives this award and 44 of the awardees have gone on to win the Nobel Prize.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 19 2019 | 4:35 PM IST

Next Story